Resveratrol promotes myogenesis and hypertrophy in murine myoblasts

Journal of Translational Medicine

Ileana Terruzzi¹  Nausicaa Mazzocchi¹  Pamela Senesi²  Livio Luzi²  Anna Montesano³ 

[1] Division of Metabolic and Cardiovascular Sciences, Metabolism, Nutrigenomics and Cellular Differentiation Unit, DIBIT-San Raffaele Scientific Institute, Milan, Italy;Metabolism Research Centre and Department of Endocrinology and Metabolic Diseases, San Donato Hospital and Scientific Institute, Milan, Italy;Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

关键词: Hypertrophy;    Myotube;    Myogenic Regulatory Factors;    Myocyte;    Differentiation;    Myoblast;    Proliferation;    Resveratrol;   

Others  :  824250
DOI  :  10.1186/1479-5876-11-310

 received in 2013-07-29, accepted in 2013-12-05,  发布年份 2013

【 摘 要 】

Background

Nutrigenomics elucidate the ability of bioactive food components to influence gene expression, protein synthesis, degradation and post-translational modifications.

Resveratrol (RSV), natural polyphenol found in grapes and in other fruits, has a plethora of health benefits in a variety of human diseases: cardio- and neuroprotection, immune regulation, cancer chemoprevention, DNA repair, prevention of mitochondrial disorder, avoidance of obesity-related diseases. In skeletal muscle, RSV acts on protein catabolism and muscle function, conferring resistance against oxidative stress, injury and cell death, but its action mechanisms and protein targets in myogenesis process are not completely known. Myogenesis is a dynamic multistep process regulated by Myogenic Regulator Factors (MRFs), responsible of the commitment of myogenic cell into skeletal muscle: mononucleated undifferentiated myoblasts break free from cell cycle, elongate and fuse to form multinucleated myotubes. Skeletal muscle hypertrophy can be defined as a result of an increase in the size of pre-existing skeletal muscle fibers accompanied by increased protein synthesis, mainly regulated by Insulin Like Growth Factor 1 (IGF-1), PI3-K/AKT signaling pathways.

Aim of this work was the study of RSV effects on proliferation, differentiation process and hypertrophy in C2C12 murine cells.

Methods

To study proliferative phase, cells were incubated in growth medium with/without RSV (0.1 or 25 μM) until reaching sub confluence condition (24, 48, 72 h). To examine differentiation, at 70% confluence, cells were transferred in differentiation medium both with/without RSV (0.1 or 25 μM) for 24, 48, 72, 96 hours. After 72 hours of differentiation, the genesis of hypertrophy in neo-formed myotubes was analyzed.

Results

Data showed that RSV regulates cell cycle exit and induces C2C12 muscle differentiation. Furthermore, RSV might control MRFs and muscle-specific proteins synthesis. In late differentiation, RSV has positive effects on hypertrophy: RSV stimulates IGF-1 signaling pathway, in particular AKT and ERK 1/2 protein activation, AMPK protein level and induces hypertrophic morphological changes in neo-formed myotubes modulating cytoskeletal proteins expression.

Conclusions

RSV might control cell cycle promoting myogenesis and hypertrophy in vitro, opening a novel field of application of RSV in clinical conditions characterized by chronic functional and morphological muscle impairment.

【 授权许可】

   
2013 Montesano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Knight DR, Kothary R: The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis. Skelet Muscle 2011, 1:29. BioMed Central Full Text
• [2]Bentzinger CF, Wang YX, Rudnicki MA: Building muscle: molecular regulation of myogenesis. Cold Spring Harb Perspect Biol 2012, 4(2):a008342.
• [3]Perry RL, Rudnick MA: Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci Sep 2000, 5:D750-67.
• [4]Kitzmann M, Fernandez A: Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci 2001, 58:571-579.
• [5]De Falco M, De Luca A: Involvement of cdks and cyclins in muscle differentiation. Eur J Histochem 2006, 50:19-23.
• [6]Ferri P, Barbieri E, Burattini S, Guescini M, et al.: Expression and subcellular localization of myogenic regulatory factors during the differentiation of skeletal muscle in C2C12 myoblasts. J Cell Biochem 2009, 108:1302-1317.
• [7]Berkes CA, Tapscott SJ: MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 2005, 16:585-595.
• [8]Kablar B, Krastel K, Tajbakhsh S, Rudnicki MA: Myf5 and MyoD activation define independent myogenic compartments during embryonic development. Dev Biol 2003, 258:307-318.
• [9]Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P: Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol 2006, 16(1):36-44.
• [10]Kook S-H, Choi K-C, Son Y-O, Lee K-Y, et al.: Involvement of p38 MAPK-mediated signaling in the calpeptin-mediated suppression of myogenic differentiation and fusion in C2C12 cells. Mol Cell Biochem 2008, 310:85-92.
• [11]Dedieu S, Mazères G, Cottin P, Brustis JJ: Involvement of myogenic regulator factors during fusion in the cell line C2C12. Int J Dev Biol 2002, 46:235-241.
• [12]Sartorelli V, Caretti G: Mechanisms underlying the transcriptional regulation of skeletal myogenesis. Curr Opin Genet Dev 2005, 15(5):528-535.
• [13]Ostrovsky O, Bengal E: The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J Biol Chem 2003, 278(23):21221-231.
• [14]Taulet N, Comunale F, Favard C, Charrasse S, et al.: N-cadherin/p120 catenin association at cell-cell contacts occurs in cholesterol-rich membrane domains and is required for RhoA activation and myogenesis. J Biol Chem 2009, 284(34):23137-23145.
• [15]Sjöblom B, Salmazo A, Djinović-Carugo K: Alpha-actinin structure and regulation. Cell Mol Life Sci 2008, 65(17):2688-2701.
• [16]Sanchez AM, Candau RB, Csibi A, Raibon A, et al.: The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol 2012, 303(5):C475-485.
• [17]Long YC, Cheng Z, Copps KD, White MF: Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol 2011, 31(3):430-441.
• [18]Tong JF, Yan X, Zhu MJ, Du M: AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes. J Cell Biochem 2009, 108(2):458-468.
• [19]McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387(6628):83-90.
• [20]Sartorelli V, Fulco M: Molecular and cellular determinants of skeletal muscle atrophy and hypertrophy. Sci STKE 2004, 244:re11.
• [21]Otto A, Patel K: Signalling and the control of skeletal muscle size. Exp Cell Res 2010, 316(18):3059-3066.
• [22]Nader GA: Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int J Biochem Cell Biol 2005, 37(10):1985-1996.
• [23]Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
• [24]Glass DJ: Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005, 37(10):1974-1984.
• [25]Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, et al.: Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 2006, 26:8267-8280.
• [26]Pervaiz S, Holme AL: Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009, 11(11):2851-2897.
• [27]Alarcòn de la Lastra C, Villegas I: Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007, 35:1156-1160.
• [28]Szkudelska K, Szkudelski T: Resveratrol, obesity and diabetes. Eur J Pharmacol 2010, 635:1-8.
• [29]Francine Z, Marques M, Markus MA, Morris BJ: Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 2009, 41(11):2125-2128.
• [30]Das S, Fraga CG, Das DK: Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFKappaB. Free Radic Res 2006, 40:066-1075.
• [31]Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, Gupta M: Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010, 298(3):H833-H843.
• [32]Shen M, Wu RX, Zhao L, Li J, Guo HT, Fan R, et al.: Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One 2012, 7(12):e51223.
• [33]Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A: Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 2010, 11(8):810-818.
• [34]Zhu X, Liu Q, Wang M, Liang M, Yang X, Xu X, Zou H, Qiu J: Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts. PLoS One 2011, 6(11):e27081.
• [35]Szkudelski T, Szkudelska K: Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 2011, 1215:34-39.
• [36]Shakibaei M, Shayan P, Busch F, Aldinger C, Buhrmann C, Lueders C, Mobasheri A: Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: potential role of Runx2 deacetylation. PLoS One 2012, 7(4):e35712.
• [37]Do GM, Jung UJ, Park HJ, Kwon EY, Jeon SM, McGregor RA, Choi MS: Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 2012, 56(8):1282-1291.
• [38]Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, et al.: Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011, 106(3):383-389.
• [39]Hwang JT, Kwon DY, Park OJ, Kim MS: Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr 2008, 2(4):323-326.
• [40]Lagouge M, Argmann C, Gerhart-Hines Z, et al.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127(6):1109-1122.
• [41]Dirks Naylor AJ: Cellular effects of resveratrol in skeletal muscle. Life Sci 2009, 84:637-640.
• [42]Park CE, Kim MJ, Lee JH, Min BI, et al.: Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007, 39(2):222-229.
• [43]Alamdari N, Aversa Z, Castillero E, Gurav A, Petkova V, Tizio S, Hasselgren PO: Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun 2012, 417(1):528-533.
• [44]Kim HJ, Kim IK, Song W, Lee J, Park S: The synergic effect of regular exercise and resveratrol on kainate-induced oxidative stress and seizure activity in mice. Neurochem Res 2013, 38(1):117-122.
• [45]Menzies KJ, Singh K, Saleem A, Hood DA: Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis. J Biol Chem 2013, 288(10):6968-6979.
• [46]Kaminski J, Lançon A, Aires V, Limagne E, et al.: Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts. Biochem Pharmacol 2012, 84(10):1251-1259.
• [47]Burattini S, Ferri P, Battistelli M, Curci R, et al.: C2C12 murine myoblasts as a model of skeletal muscle development: morpho-functional characterization. Eur J Histochem 2004, 48(3):223-233.
• [48]Yaffe D, Saxel O: Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270:725-727.
• [49]Sharples AP, Al-Shanti N, Stewart CE: C2 and C2C12 murine skeletal myoblast models of atrophic and hypertrophic potential: relevance to disease and ageing? J Cell Physiol 2010, 225(1):240-250.
• [50]Sharples AP, Stewart CE: Myoblast models of skeletal muscle hypertrophy and atrophy. Curr Opin Clin Nutr Metab Care 2011, 14(3):230-236.
• [51]Senesi P, Luzi L, Montesano A, Mazzocchi N, Terruzzi I: Betaine supplement enhances skeletal muscle differentiation in murine myoblasts via IGF-1 signaling activation. J Transl Med 2013, 11(1):174. BioMed Central Full Text
• [52]Montesano A, Luzi L, Senesi P, Terruzzi I: Modulation of cell cycle progression by 5-azacytidine is associated with early myogenesis induction in murine myoblasts. Int J Biol Sci 2013, 9(4):391-402.
• [53]Terruzzi I, Senesi P, Magni C, Montesano A, et al.: Insulin-mimetic action of Conglutin-γ, a lupin seed protein, in mouse myoblasts. Nutr Metab Cardiovasc Dis 2010, 21(3):197-205.
• [54]Gotz C, Montenarh M: p53 and its implication in apoptosis (review). Int J Oncol 1995, 6(5):1129-1135.
• [55]Figliola R, Maione R: MyoD induces the expression of p57Kip2 in cells lacking p21Cip1/Waf1: overlapping and distinct functions of the two cdk inhibitors. J Cell Physiol 2004, 200(3):468-475.
• [56]Halevy O, Novitch BG, Spicer DB, Skapek SX: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995, 267(5200):1018-1021.
• [57]Jansen KM, Pavlath GK: Molecular control of mammalian myoblast fusion. Methods Mol Biol 2008, 475:115-133.
• [58]Rochlin K, Yu S, Roy S, Baylies MK: Myoblast fusion: when it takes more to make one. Dev Biol 2010, 341(1):66-83.
• [59]Tanaka K, Sato K, Yoshida T, Fukuda T, et al.: Evidence for cell density affecting C2C12 myogenesis: possible regulation of myogenesis by cell-cell communication. Muscle Nerve 2011, 44(6):968-977.
• [60]Knudsen KA, Myers L, McElwee SA: A role for the Ca2(+)-dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis. Exp Cell Res 1990, 188(2):175-184.
• [61]Rommel C, Bodine SC, Clarke BA, Rossman R, et al.: Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001, 3(11):1009-1013.
• [62]Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR: The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997, 272(10):6653-6662.
• [63]Metzger T, Gache V, Xu M, Cadot B, et al.: MAP and kinesin-dependent nuclear positioning is required for skeletal muscle function. Nature 2012, 484(7392):120-124.
• [64]Li J, Johnson SE: ERK2 is required for efficient terminal differentiation of skeletal myoblasts. Biochem Biophys Res Commun 2006, 345(4):1425-1433.
• [65]Folker ES, Schulman VK, Baylies MK: Muscle length and myonuclear position are independently regulated by distinct Dynein pathways. Development 2012, 139(20):3827-3837.
• [66]Buckingham M: How the community effect orchestrates muscle differentiation. Bioessays 2002, 25:13-16.
• [67]Chargè S, Rudnicki M: Cellular and molecular regulation of muscle regeneration. Physiol Rev 2004, 84(1):209-238.
• [68]Ye F, Mathur S, Liu M, Borst SE, Walter GA, Sweeney HL, Vandenborne K: Overexpression of IGF-1 attenuates skeletal muscle damage and accelerates muscle regeneration and functional recovery after disuse. Exp Physiol 2013, 98(5):1038-1052.
• [69]Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, et al.: Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004, 24:9295-9304.
• [70]Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, et al.: High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62(4):1186-1195.